Samjin pharm announced on the 18th that it has entered into a sales partnership agreement to distribute influenza vaccines domestically with CSL Seqirus Korea, a global vaccine corporation. The company plans to expand vaccine distribution starting with this agreement.
The vaccines that Samjin pharm will be responsible for distributing include CSL Seqirus's adjuvanted influenza vaccine, "Fluad® Quad prefilled syringe," and the cell-cultured influenza vaccine, "Flucelvax® Quad prefilled syringe."
CSL Seqirus Korea stated it will utilize Samjin pharm's domestic sales and marketing network to provide influenza vaccine benefits to more patients. Samjin pharm will handle the marketing and publicity for Fluad and Flucelvax, and domestic distribution will be conducted jointly with CSL Seqirus Korea, which is responsible for importing the vaccines.
CSL Seqirus is a company specializing in influenza vaccines. Its parent company, CSL, was established in Australia in 1916. CSL Seqirus was formed in 2015 after the merger of Novartis's influenza vaccine division and CSL's vaccine subsidiary, BioCSL.
Ahead of the influenza vaccine season in October, Samjin pharm plans to enhance communication and education through specialized channels, including hosting conferences and symposiums for healthcare professionals and running online webinars. Advertising campaigns targeting the public are also in preparation.
Fluad is an influenza vaccine that includes an adjuvant to enhance immunity and was approved by the Ministry of Food and Drug Safety for use in individuals aged 65 and older in September 2022. One advantage of Fluad is that it can maintain its preventive effect for up to one year.
Flucelvax is the world's first cell-cultured influenza vaccine, which was approved for use in children aged 2 and older and adults for influenza prevention last August in Korea. It has been clinically proven to be safe for patients with severe egg allergies as it is not produced from eggs like traditional vaccines. Flucelvax is expected to be launched in Korea during the 2025-26 season.
Yoo Gi-seung, CEO of CSL Seqirus Korea, noted, "Through this agreement, CSL Seqirus Korea expects to supply the differentiated influenza vaccines, Fluad and Flucelvax, to more citizens" and added, "We will closely cooperate with Samjin pharm in the future to contribute to the improvement of public health in Korea."
Kim Sang-jin, president of Samjin pharm, said, "Through this collaboration, Samjin pharm has laid the groundwork to expand its business scope beyond the existing treatment-centered areas into the prevention-focused vaccine sector" and stated, "In the future, we will stably supply the safe and effective influenza vaccines, Fluad and Flucelvax, recognized globally for their research and supply capabilities by CSL Seqirus Korea."